Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 52Radiotherapy 24Bevacizumab 23Radiation 10Magnetic Resonance Spectroscopy 7Lomustine 7Carmustine 7Radiosurgery 6Surgical Procedures, Operative 5Irinotecan 5Aminolevulinic Acid 5Radiotherapy, Intensity-Modulated 4Nivolumab 4Ipilimumab 4Erlotinib Hydrochloride 4Cilengitide 4vocimagene amiretrorepvec 3vitespin 3sargramostim 3poly ICLC 3pembrolizumab 3fluoromisonidazole 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3TPI-287 3O(6)-benzylguanine 3Granulocyte-Macrophage Colony-Stimulating Factor 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡